APA (7th ed.) Citation

Gleeson, M., Counsell, N., Cunningham, D., Lawrie, A., Clifton‐Hadley, L., Hawkes, E., . . . Linch, D. (2021). Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: An analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial. British Journal of Haematology, 192(6), 1015. https://doi.org/10.1111/bjh.16691

Chicago Style (17th ed.) Citation

Gleeson, Mary, et al. "Prognostic Indices in Diffuse Large B‐cell Lymphoma in the Rituximab Era: An Analysis of the UK National Cancer Research Institute R‐CHOP 14 Versus 21 Phase 3 Trial." British Journal of Haematology 192, no. 6 (2021): 1015. https://doi.org/10.1111/bjh.16691.

MLA (9th ed.) Citation

Gleeson, Mary, et al. "Prognostic Indices in Diffuse Large B‐cell Lymphoma in the Rituximab Era: An Analysis of the UK National Cancer Research Institute R‐CHOP 14 Versus 21 Phase 3 Trial." British Journal of Haematology, vol. 192, no. 6, 2021, p. 1015, https://doi.org/10.1111/bjh.16691.